AR
RXRX icon

Advisory Research’s Recursion Pharmaceuticals RXRX Stock Holding History

Advisory Research’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-135,683
Closed -$1.01M – 475
2023
Q2 		$1.01M Buy
+135,683
New +$949K 0.13% 200
2022
Q4 		– Sell
-96,803
Closed -$1.03M – 399
2022
Q3 		$1.03M Buy
96,803
+34,999
+57% +$354K 0.1% 163
2022
Q2 		$503K Buy
+61,804
New +$414K 0.05% 229

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Advisory Research's RXRX Position: Q3 2023 in Review

Advisory Research sold out of Recursion Pharmaceuticals (RXRX) in Q3 2023, closing a stake of 135,683 shares — an estimated $1.01M sold.

Advisory Research first reported a position in RXRX in Q2 2022 and held it in 3 quarters. The position peaked at $1.03M in Q3 2022. 192 funds tracked by Wall St. Rank hold RXRX as of Q3 2023.

  • Advisory Research reported no remaining Recursion Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Advisory Research sold 135,683 Recursion Pharmaceuticals shares in Q3 2023, an estimated $1.01M.
  • Advisory Research first reported a position in Recursion Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Advisory Research's Recursion Pharmaceuticals position peaked at $1.03M in Q3 2022.
  • 192 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2023.

Based on Advisory Research's 13F filing for Q3 2023, filed 13 Nov 2023.